A kidney cancer drug from Aveo Pharmaceuticals (AVEO) outperformed an approved drug from Onyx...


A kidney cancer drug from Aveo Pharmaceuticals (AVEO) outperformed an approved drug from Onyx Pharmaceuticals (ONXX) in a late-stage study comparing the two treatments head-to-head. Based on these data, the firm says it plans to submit for marketing approval of tivozanib in the United States and Europe this year.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs